anastrozole has been researched along with Cancer, Second Primary in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patient acceptance of SERMs for breast cancer prevention is low due to toxicities." | 5.38 | Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. ( Akar, U; Arun, B; Brewster, A; Buzdar, AU; Esteva, FJ; Green, M; Gutierrez-Barrera, A; Hortobagyi, GN; Liu, D; Rivera, E; Sneige, N; Valero, V, 2012) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | 3.73 | t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| "Patient acceptance of SERMs for breast cancer prevention is low due to toxicities." | 1.38 | Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. ( Akar, U; Arun, B; Brewster, A; Buzdar, AU; Esteva, FJ; Green, M; Gutierrez-Barrera, A; Hortobagyi, GN; Liu, D; Rivera, E; Sneige, N; Valero, V, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Iwase, T | 1 |
| Saji, S | 1 |
| Iijima, K | 1 |
| Higaki, K | 1 |
| Ohtani, S | 1 |
| Sato, Y | 1 |
| Hozumi, Y | 1 |
| Hasegawa, Y | 1 |
| Yanagita, Y | 1 |
| Takei, H | 1 |
| Tanaka, M | 1 |
| Masuoka, H | 1 |
| Tanabe, M | 1 |
| Egawa, C | 1 |
| Komoike, Y | 1 |
| Nakamura, T | 1 |
| Ohtsu, H | 1 |
| Mukai, H | 1 |
| Gottwald, L | 1 |
| Gora, E | 1 |
| Korczynski, J | 1 |
| Piekarski, JH | 1 |
| Morawiec, Z | 1 |
| Jesionek-Kupnicka, D | 1 |
| Sowa, P | 1 |
| Cialkowska-Rysz, A | 1 |
| Bienkiewicz, A | 1 |
| Arun, B | 1 |
| Valero, V | 1 |
| Liu, D | 1 |
| Brewster, A | 1 |
| Green, M | 1 |
| Gutierrez-Barrera, A | 1 |
| Akar, U | 1 |
| Rivera, E | 1 |
| Esteva, FJ | 1 |
| Buzdar, AU | 1 |
| Hortobagyi, GN | 1 |
| Sneige, N | 1 |
| Baron, M | 1 |
| Dessogne, P | 1 |
| d'Anjou, J | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| Sahin, FI | 1 |
| Yilmaz, Z | 1 |
| Karakuş, S | 1 |
| Boğa, S | 1 |
| Akçali, Z | 1 |
| DemIrhan, B | 1 |
| Perez, EA | 1 |
1 review available for anastrozole and Cancer, Second Primary
| Article | Year |
|---|---|
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
1 trial available for anastrozole and Cancer, Second Primary
| Article | Year |
|---|---|
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast N | 2023 |
5 other studies available for anastrozole and Cancer, Second Primary
| Article | Year |
|---|---|
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.
Topics: Aged; Anastrozole; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Gastrointestinal Str | 2008 |
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Topics: Aged; Anastrozole; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast N | 2012 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinos | 2004 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |